{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:50:23Z","timestamp":1790776223686,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2014,5,22]],"date-time":"2014-05-22T00:00:00Z","timestamp":1400716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["Z99 CA999999"],"award-info":[{"award-number":["Z99 CA999999"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2014,8,15]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>To evaluate whether progress continues in identifying more effective treatments for children and adolescents with cancer, the authors examined both overall and disease\u2010specific childhood cancer mortality rates for the United States, focusing on data from 2000 to 2010.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Age\u2010adjusted US mortality trends from 1975 to 2010 were estimated using joinpoint regression analysis. Analyses of annual percentage change (APC) were performed on the same diagnostic groupings for the period restricted to 2000 through 2010 for groupings ages &lt;20 years, &lt;15 years, and 15 to 19 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>After a plateau in mortality rates during 1998 to 2002 (APC, 0.3%), the annual decline in childhood cancer mortality from 2002 to 2010 (APC, \u22122.4%) was similar to that observed from 1975 to 1998 (APC, \u22122.7%). Statistically significant declines in mortality rates from 2000 to 2010 were noted for acute lymphoblastic leukemia, acute myeloid leukemia, non\u2010Hodgkin lymphoma, Hodgkin lymphoma, neuroblastoma, central nervous system cancers, and gonadal cancers. From 2000 to 2010, the rates of decline in mortality for the group ages 15 to 19 years generally were equal to or greater than the rates of decline for the group ages birth to 14 years. Improvements in treatment since 1975 resulted &gt;45,000 cancer deaths averted through 2010.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Cancer mortality for both children and adolescents declined from 2000 to 2010, with significant declines observed for multiple cancer types. However, greater than 1900 cancer deaths still occur each year among children and adolescents in the United States, and many survivors experience long\u2010term effects that limit their quality of life. Continued research directed toward identifying more effective treatments that produce fewer long\u2010term sequelae is critical to address these remaining challenges. <jats:bold><jats:italic>Cancer<\/jats:italic> 2014;120:2497\u20132506<\/jats:bold>. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.28748","type":"journal-article","created":{"date-parts":[[2014,5,22]],"date-time":"2014-05-22T10:42:47Z","timestamp":1400755367000},"page":"2497-2506","source":"Crossref","is-referenced-by-count":472,"title":["Declining childhood and adolescent cancer mortality"],"prefix":"10.1002","volume":"120","author":[{"given":"Malcolm A.","family":"Smith","sequence":"first","affiliation":[{"name":"Cancer Therapy Evaluation Program National Cancer Institute Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean F.","family":"Altekruse","sequence":"additional","affiliation":[{"name":"Surveillance Research Program National Cancer Institute Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Adamson","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics Children's Hospital of Philadelphia Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory H.","family":"Reaman","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nita L.","family":"Seibel","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program National Cancer Institute Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,5,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.0421"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70010-X"},{"key":"e_1_2_7_4_1","unstructured":"National Cancer Institute;Surveillance Epidemiology and End Results (SEER) Population Estimates Used in NCI's SEER*Stat Software. Available at:http:\/\/seer.cancer.gov\/popdata\/methods.html. Accessed September 1 2012."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds183"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2454"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-322909"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-070342"},{"key":"e_1_2_7_10_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.18_suppl.3","article-title":"Comparison of high\u2010dose methotrexate (HD\u2010MTX) with Capizzi methotrexate plus asparaginase (C\u2010MTX\/ASNase) in children and young adults with high\u2010risk acute lymphoblastic leukemia (HR\u2010ALL): a report from the Children's Oncology Group Study AALL0232 [abstract]","volume":"29","author":"Larsen EC","year":"2011","journal-title":"J Clin Oncol."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.2514"},{"key":"e_1_2_7_12_1","article-title":"Improved early event free survival (EFS) in children with Philadelphia chromosome\u2010positive (Ph+) acute lymphoblastic leukemia (ALL) with intensive imatinib in combination with high dose chemotherapy: Children's Oncology Group (COG) Study AALL0031 [abstract]","volume":"110","author":"Schultz KR","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.5703"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21459"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-130237"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8959"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6768"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-410746"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-269621"},{"key":"e_1_2_7_20_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.9500","article-title":"Efficacy of crizotinib in children with relapsed\/refractory ALK\u2010driven tumors including anaplastic large cell lymphoma and neuroblastoma: a Children's Oncology Group phase I consortium study [abstract]","volume":"30","author":"Mosse YP","year":"2012","journal-title":"J Clin Oncol."},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0911123"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/08880018.2011.596615"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2012.00003"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1920"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq007"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI33656"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-011-0802-6"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-012-0998-0"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10833"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.1102"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07385"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164382"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001707"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.28748","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.28748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T22:58:34Z","timestamp":1760309914000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.28748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,22]]},"references-count":33,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2014,8,15]]}},"alternative-id":["10.1002\/cncr.28748"],"URL":"https:\/\/doi.org\/10.1002\/cncr.28748","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,22]]}}}